EQL Pharma AB

Prospectus • Nov 17, 2025

Press release

Lund 17 November 2025 EQL Pharma AB Reg. No. 556713-3425

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

EQL Pharma AB (publ) publishes prospectus and applies for admission to trading of bonds on the corporate bond list of Nasdaq Stockholm

On 24 January 2025, EQL Pharma AB (publ) (the "Company") issued senior secured bonds of SEK 350 million (the "Bonds"). The Bonds have been admitted to trading on the Transfer Market segment of Nasdaq First North Bond Market since 25 February 2025. In accordance with the terms and conditions of the Bonds, the Company has today submitted an application for admission to trading of the Bonds on the corporate bond list of Nasdaq Stockholm.

The first day of trading in the Bonds on the corporate bond list of Nasdaq Stockholm is expected to be on or around 19 November 2025. In connection therewith, the Bonds will cease to be traded on the Transfer Market segment of Nasdaq First North Bond Market.

On account of the application for admission to trading of the Bonds on the corporate bond list of Nasdaq Stockholm, the Company has prepared a prospectus for the Bonds. The prospectus has today been approved by and registered with the Swedish Financial Supervisory Authority. The prospectus will be available at the Company's website, https://investor.eqlpharma.com/, and at the Swedish Financial Supervisory Authority's website, https://www.fi.se/en/.

For additional information, please contact:

Axel Schörling President and CEO EQL Pharma AB (publ)

Phone: +46 (0) 76 317 90 60

E-Mail: axel.schorling@eqlpharma.com

Website: www.eqlpharma.com

EQL Pharma AB (publ) briefly

EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has 46 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2025 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, mainly in the Nordics and European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm stock market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.